Business

EGM Statement

EGM Statement.

articleHikma Pharmaceuticals PlcFebruary 19, 20163/company/hikma-pharmaceuticals-plc/news/egm-statement-17
EGM Statement

About this update from Hikma Pharmaceuticals Plc

[{"type":"text","content":"\n \nRNS Number : 6239P Hikma Pharmaceuticals Plc 19 February 2016  \n\n \nHikma Pharmaceuticals PLC\nVoting Results of Extraordinary General Meeting\nLondon, 19 February 2016 - Hikma Pharmaceuticals PLC (\"Hikma\" or the \"Company\") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, announced on 28 July 2015 that it had agreed terms to acquire Roxane Laboratories Inc. and Boehringer Ingelheim Roxane Inc. from Boehringer Ingelheim (the \"Acquisition\").\nThe Company is pleased to announce that, at the General Meeting held today, the resolutions (the \"Resolutions\") in respect of the Acquisition were decided on a poll and passed as ordinary resolutions. Details of the Resolutions were set out in the combined prospectus and circular published on 22 January 2016 and posted to shareholders on 25 January 2016 (the \"Prospectus\") and the supplementary prospectus and circular which was published and sent to shareholders on 11 February 2016. Completion of the Acquisition is expected to take place on 29 February 2016. \nThe total number of votes cast on the poll for each resolution is set out below. \n\n\n\n\n\n\n\nResolution\n\n\nFor \n\n\nAgainst\n\n\nVotes withheld\n\n\nTotal votes cast\n\n\n\n\nVotes\n\n\n%\n\n\nVotes\n\n\n%\n\n\n\n\n1.\n\n\nApproving the transaction\n\n\n157,068,100\n\n\n99.98%\n\n\n31,346\n\n\n0.02%\n\n\n491,344\n\n\n157,099,446\n\n\n\n\n2.\n\n\nGranting the Directors authority to allot the Consideration Shares\n\n\n157,078,102\n\n\n99.99%\n\n\n21,344\n\n\n0.01%\n\n\n491,344\n\n\n157,099,446\n\n\n\n\n3.\n\n\nApproving the off-market purchase contract and off-market purchase by the Company of its own shares\n\n\n157,049,321\n\n\n99.97%\n\n\n50,341\n\n\n0.03%\n\n\n491,128\n\n\n157,099,662\n\n\n\n\nNotes:\nAs at 19 February 2016, the Company's issued share capital was 199,385,501 ordinary shares of 10 pence each.\n1.  Votes withheld are not votes under English law and so have not been included in the calculation of the votes case \"For\" or \"Against\" the Resolution.\n2.  Percentages are expressed as a proportion of the total votes cast and have been rounded to two decimal places.\nCompletion of the Acquisition remains subject to the satisfaction or waiver of certain other conditions, including the expiration of any HSR Act antitrust waiting period...

More updates from Hikma Pharmaceuticals Plc